Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly (QW)
Brief Summary: The purpose of this study objective will be to evaluate the efficacy and safety of etanercept 50 mg BIW in RA subjects who showed a sub-optimal response to standard dose etanercept (50 mg QW) and concomitant methotrexate therapy.


Options:
A: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
B: Arm Label: Open Label Infliximab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Infliximab + methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Infliximab + methotrexate (MTX); Assigned to Arm(s): Open Label Infliximab + Methotrexate
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: MTX | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Infliximab, Drug: MTX | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 2
D: Arm Label: CDP6038 60 mg sc every 2 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo iv | Arm Label: CDP6038 60 mg sc every 4 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo sc, Other: Placebo iv | Arm Label: CDP6038 120 mg sc every 2 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo iv | Arm Label: CDP6038 120 mg sc every 4 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo sc, Other: Placebo iv | Arm Label: CDP6038 240 mg sc every 2 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo iv | Arm Label: CDP6038 240 mg sc every 4 weeks plus methotrexate; Type: EXPERIMENTAL; Interventions: Biological: CDP6038, Other: Placebo sc, Other: Placebo iv | Arm Label: Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: Tocilizumab (Actemra or RoActemra), Other: Placebo sc | Arm Label: Placebo sc every 2 weeks plus methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo sc, Other: Placebo iv | Arm Label: Placebo sc every 4 weeks plus methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo sc, Other: Placebo iv | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 60 mg sc every 2 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 120 mg sc every 2 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 240 mg sc every 2 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: Tocilizumab (Actemra or RoActemra); Assigned to Arm(s): Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 60 mg sc every 4 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 240 mg sc every 4 weeks plus methotrexate | Intervention Type: BIOLOGICAL; Name: CDP6038; Assigned to Arm(s): CDP6038 120 mg sc every 4 weeks plus methotrexate | Intervention Type: OTHER; Name: Placebo sc; Assigned to Arm(s): Placebo sc every 2 weeks plus methotrexate, Placebo sc every 4 weeks plus methotrexate, Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate | Intervention Type: OTHER; Name: Placebo sc; Assigned to Arm(s): CDP6038 120 mg sc every 4 weeks plus methotrexate, CDP6038 240 mg sc every 4 weeks plus methotrexate, CDP6038 60 mg sc every 4 weeks plus methotrexate | Intervention Type: OTHER; Name: Placebo iv; Assigned to Arm(s): CDP6038 120 mg sc every 2 weeks plus methotrexate, CDP6038 120 mg sc every 4 weeks plus methotrexate, CDP6038 240 mg sc every 2 weeks plus methotrexate, CDP6038 240 mg sc every 4 weeks plus methotrexate, CDP6038 60 mg sc every 2 weeks plus methotrexate, CDP6038 60 mg sc every 4 weeks plus methotrexate, Placebo sc every 2 weeks plus methotrexate, Placebo sc every 4 weeks plus methotrexate

Answer: A